Navigation Links
WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category

SARASOTA, Fla., April 21 /PRNewswire/ -- WellSpring Pharmaceutical Corporation announced earlier today that Emetrol (R), its liquid anti-nausea brand is now the leading product in its category. Based on trailing 52 weeks sales (ending 1/14/09) Emetrol(R) garnered 51.7 % of the brand category displacing all others including private label. The most recent IRI reports indicate that Emetrol (R) sales are up 24% over last year reflecting the fact that it is recommended by name by OB/GYN's, Pediatricians and Pharmacists. Over 90% of OB/GYN's interviewed indicate that they would most likely use Emetrol(R) as first line therapy in treating mild to moderate nausea.

For over 60 years, Emetrol(R) has provided consumers with reliable relief from nausea and vomiting. Emetrol (R) is popular with more and more consumers including women between the ages of 25 and 34 who seek Emetrol(R) due to their doctor or pharmacist's recommendation. Emetrol(R) is specifically recommended because it is safe, effective, and gives fast relief from nausea and vomiting due to upset stomach, flu, and food indiscretions. WellSpring has rolled out a national advertising campaign targeting this population segment. And the National Association of Pediatric Nurse Practitioners (NAPNAP) has selected Emetrol(R) for editorial content in their upcoming issue which reaches 3.5 million women ages 25-48.

WellSpring's President and CEO, Dr. Robert A. Vukovich commented on this announcement: "The Emetrol(R) brand is an important one for our company as we have seen remarkable growth in its sales over this past year. The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by Pediatricians for children under their care, has proven to be one of the most important attributes of the brand. Containing a unique combination of phosphorylated carbohydrates Emetrol (R) is considered by these physicians as safe and effective for treating mild to moderate nausea. We will continue to invest heavily in the brand with a new national advertising campaign."

WellSpring Pharmaceutical Corporation is a closely held pharmaceutical company marketing both prescription and non-prescription consumer drug brands. The firm has headquarters in Sarasota, Florida and operates a state-of-the-art GMP compliant manufacturing facility in Canada.


    Wendy Shusko, COO 941-312-4727
    Wayne Miller, VP Sales 941-312-4727

    WellSpring Pharmaceutical Corporation
    5911 North Honore Ave., Ste 211
    Sarasota, Fl  34243

Emetrol Website:

SOURCE WellSpring Pharmaceutical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
2. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
3. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
4. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
5. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
6. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
7. Strativa Pharmaceuticals Provides Product Pipeline Update
8. Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
10. Sun Pharmaceutical Extends Tender Offer for Taro
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... SAN ... today announced that the organization has awarded Education and Developmental Therapies (EDT), an ... Award. The award celebrates exceptional special needs providers that excel in synthesizing the ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies ... and population health arenas, is pleased to announce that VIP Care Services, a ... successfully implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case ...
(Date:12/1/2015)... Viejo, CA (PRWEB) , ... December 01, 2015 , ... ... length of footage, and with full control over customization, the possibilities are truly endless, ... frame rate, position randomization, overlay depth position, vertical flip, horizontal flip, depth of field ...
(Date:12/1/2015)... Chicago, IL (PRWEB) , ... December 01, 2015 ... ... the Unified Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This ... sell, deploy and support Cisco Unified Contact Center solutions targeted to the high-end ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... The Turks ... Journal, one of the leading digital news sites highlighting Caribbean destinations, has published five ... While much of North America shivers under chilly grey skies or worse, it's ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Assurex Health, Inc. today announced a ... providers an expanded range of options in helping ... depression, anxiety, bipolar disorder, posttraumatic stress disorder (PTSD), ... i .   --> i ... of two new drug classes, 17 FDA-approved medications ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
Breaking Medicine Technology: